

Consolidated Financial Results for the Six Months Ended September 30, 2024

Securities Code: 7780

Menicon Co., Ltd. November 13, 2024

•



- I Summary of Consolidated Financial Results for 2Q FY2024
- Forecast of Consolidated Financial Results for FY2024





I . Summary of Consolidated Financial Results for 2Q FY2024

Summary of Consolidated Financial Results for FY2024 2Q

(JPY mn)	FY2023 2Q	FY2024 2Q	ΥοΥ
Net sales	58,126	60,571	+4.2%
Cost of sales	27,674	27,770	+0.3%
[Cost of sales ratio]	47.6%	45.8%	[-1.8pt]
Gross profit	30,451	32,801	+7.7%
SGA	25,197	27,313	+8.4%
[SGA ratio]	43.3%	45.1%	[+1.8pt]
Operating profit	5,253	5,487	+4.5%
[Operating profit margin]	9.0%	9.1%	[+0.1pt]
EBITDA	9,061	9,455	+4.4%
[EBITDA margin]	15.6%	15.6%	[±0.0pt]
Ordinary profit	4,952	5,618	+13.4%
Profit attributable to owners of parent	3,321	3,622	+9.0%

* EBITDA is calculated from operating profit, depreciation and amortization of goodwill, etc.


(Reference) Past figures are available in the following data book. https://www.menicon.com/corporate/ir/databook

3



Key Factors

1DAY-lens sales increased in Japan and orthokeratology-related sales increased due to sales expansion in Japan/Singapore/Korea. Operating profit and EBITDA increased due to sales expansion and price revisions in Japan, even after making investments for future growth.



Breakdown of Net Sales



5

•

(JPY mn)	FY2023 2Q	FY2024 2Q	YoY
Net sales	58,126	60,571	+4.2%
Vision Care	53,037	56,295	+6.1%
1DAY-lens	14,055	15,389	+9.5%
Japan_MELS Plan*1	10,222	11,195	+9.5%
Japan_Product sales*2	2,242	2,777	+23.9%
Overseas	1,590	1,416	-10.9%
Orthokeratology-related	7,496	7,656	+2.1%
Ortho-K (Global)	2,628	2,840	+8.1%
Lens care products (Asia)	4,868	4,816	-1.1%
Other Contact lenses and Lens care products	31,486	33,249	+5.6%
MELS Plan*1	12,816	13,687	+6.8%
Contact lenses	13,581	14,110	+3.9%
Lens care products (Non-Asia)	5,088	5,450	+7.1%
Healthcare and Life Care	5,088	4,276	-16.0%


Consolidated Net Sales



Growth due to expansion of 1DAY-lens sales and effect of price revision in Japan.




(2) Ortho-K-related



1DAY-lens Sales (Breakdown of Sales)

Growth due to increase in number of MELS Plan members and effect of price revision in Japan.

Nenicon




Total Number of MELS Plan Members

Increased average monthly fee due to higher ratio of high-unit-price 1DAY-lens members and price revisions.

Nenicon

8






Growth due to expansion of Ortho-K sales in Japan/Singapore/Korea.

(JPY bn) ■ (1) Ortho-K (Global)

(2) Lens care products (Asia)



1 Ortho-K (Global) (YoY : JPY +0.21 bn)

- China : Maintained sales to distributors, foreign exchange impact (JPY +0.07 bn)
- Japan : Expanded the number of facilities handled (JPY +0.07 bn)

Singapore/South Korea : Increased sales (JPY +0.05 bn)

2 Lens care products (Asia) (YoY : JPY -0.05 bn)

China: Suffered a decreased in sales due to deteriorated competitive environment and economic stagnation (JPY -0.04 bn)

Copyright: Menicon Co., Ltd. All rights reserved.

٠


Nenicon

Vision Care

Other Contact Lenses and Lens Care Products (Breakdown of Sales)

Growth due to expansion of 1MONTH-lens sales in Europe and effect of price revision in Japan. (1) MELS Plan


- (JPY bn) (2) Contact lenses
 - (3) Lens care products (Non-Asia)



Healthcare and Life Care

Healthcare and Life Care Net Sales

Decrease in sales due to the scale reduction of the Food business in China, etc.




Nenicon

Operating Profit and EBITDA

S Menicon

12

Increased due to expansion of 1DAY-lens sales, etc. and effect of price revision in Japan, even after making investments for future growth.




Operating profit (YoY : JPY **+0.23** bn)

Operating profit margin (YoY : **-0.1** pt)

- Gross profit : JPY +2.34 bn (JPY 30.4 bn → JPY 32.8 bn) Sales expansion of 1DAY-lens, etc., effect of price revision in Japan
- SGA :JPY +2.11 bn (JPY 25.1 bn → JPY 27.3 bn) Strengthening of investment for growth (new plants, personnel reinforcement, R&D)
- 2 EBITDA (YoY : JPY **+0.39** bn) EBITDA margin (YoY : **±0.0** pt)
- Depreciation : JPY +0.12 bn (JPY 3.60 bn → JPY 3.73 bn) Increase due to 1DAY-lens investment, etc.

Analysis of Changes in Consolidated Gross Profit

Increased due to expansion of sales and effect of price revision in Japan.



Nenicon


13

• Main reasons for increase/decrease *Including foreign exchange impact

	Items		
1DAY-lens	Increased in number of MELS Plan members, expansion of product sales in Japan, and effect of price revision in Japan		
Orthokeratology-related	Expanded Ortho-K sales in global markets		
Other Contact lenses and Lens care products	Expanded sales in Europe and effect of price revision in Japan		
Healthcare and Life Care	Decreased in Food business scale in China		

Analysis of Changes in Operating Profit

Increased operating profit even after making investment for future growth.




Major breakdown of SGA expenses (constant) *Including foreign exchange impact

• Major breakdown of investment for future growth *Including foreign exchange impact

	ltoms	Amount (JPY bn)	Itoms	Amount (JPY bn)
Office outsourcing	Costs of Distribution center in Europe and M&A related, etc.	(0.3)	New plant 1DAY-lens preparation for the operation of the Malaysia plant, a new production site.	(0.2)
fee Rent	Start of Global Logistics Center operation, etc.	(0.1)	Personnel reinforcement Wage increases, personnel increases, etc. in Japan and overseas	(0.5)
			R&DDevelopment and clinical trial expenses for new products, increase in research personnel, etc.(0.4)	
↓↓↓	👀 🖏 ∔ 🧯 🤒 🔸 🧶 🐐	∔ .		÷ .



Summary of Consolidated Balance Sheet




Aenicon

Consolidated Cash Flow Comparison



16

•





II. Forecast of Consolidated Financial Results and Outlook for FY2024

Breakdown of Net Sales Forecast



18

No change from the consolidated earnings forecast (Net sales).

The breakdown of net sales forecast has been revised, reflecting the current situation (announced on November 13, 2024).

(JPY mn)	FY2024 (1) Previous forecast	FY2024 (2) Revised forecast	FY2024 Change (2)-(1)
Net sales	122,700	122,700	-
Vision Care	115,100	114,100	(1,000)
1DAY-lens	32,000	31,600	(400)
MELS Plan	23,400	23,000	(400)
Product sales in Japan	5,100	5,500	+400
Overseas	3,500	3,100	(400)
Orthokeratology-related	15,600	14,500	(1,100)
Other Contact lenses and Lens care products	67,500	68,000	+500
Healthcare and Life Care	7,600	8,600	+1,000

(Reference) MELS Plan sales for FY2024: JPY 50.8 bn (forecast as of May 14, 2024)⇒JPY 50.0 bn (announced on Nov. 13, 2024)

Financial Forecast



19

No change from the consolidated financial forecast (net sales, operating profit and other line-item profits below). Cost of sales and SGA forecasts have been revised, reflecting the current situation (announced on November 13, 2024).

(JPY mn)	FY2024 (1) Previous forecast	FY2024 (2) Revised forecast	FY2024 Change (2)-(1)
Net sales	122,700	122,700	-
Cost of sales	57,500	57,800	+300
[Cost of sales ratio]	46.9%	47.1%	[+0.2%]
Gross profit	65,200	64,900	(300)
Selling, general and administrative expenses	55,200	54,900	(300)
[SGA Ratio]	45.0%	44.7%	[-0.3%]
Operating profit	10,000	10,000	-
[Operating profit margin]	8.1%	8.1%	-
EBITDA	20,437	19,600	(837)
[EBITDA margin]	16.7%	16.0%	[-0.7%]
Ordinary profit	9,500	9,500	-
Profit attributable to owners of parent	7,000	7,000	-
 * Exchange rates in FY2023 Exchange rates in assumed in financial forecast FY2024 <l< td=""><td></td><td>PY 145.3, CNY: JPY 19.9 PY 147.0, CNY: JPY 20.3</td><td>ò ∔ 🐠 📀</td></l<>		PY 145.3, CNY: JPY 19.9 PY 147.0, CNY: JPY 20.3	ò ∔ 🐠 📀

Financial Forecast and Progress



20

(JPY mn)	FY2023	FY2024 2Q	FY2024 (Revised forecast)	Progress rate
Net sales	116,192	60,571	122,700	49.4%
Cost of sales	55,181	27,770	57,800	48.0%
(Cost of Sales Ratio)	47.5%	45.8%	47.1%	
Gross profit	61,010	32,801	64,900	50.5%
Selling, general and administrative expenses	52,058	27,313	54,900	49.8%
(SGA Ratio)	44.8%	45.1%	44.7%	
Operating profit	8,951	5,487	10,000	54.9%
(Operating profit margin)	7.7%	9.1%	8.1%	
EBITDA	17,048	9,455	19,600	48.2%
(EBITDA margin)	14.7%	15.6%	16.0%	
Ordinary profit	8,225	5,618	9,500	59.1%
Profit attributable to owners of parent	4,538	3,622	7,000	51.7%
*Exchange rates in FY2023 Exchange rates in 2Q FY2024 Exchange rates assumed in financial forecast F	EUR: JP	Y 165.8, USD: JP	 ✓ 145.3, CNY: JPY 19.9 ✓ 152.5, CNY: JPY 21.3 ✓ 147.0, CNY: JPY 20.3 ✓ ● ◆ ● 	🗼 🐠 👧 ∔



(JPY mn)	FY2023	FY2024 2Q	FY2024 (Revised forecast)	Progress rate
Net sales	116,192	60,571	122,700	49.4%
Vision Care	106,887	56,295	114,100	49.3%
1DAY-lens	28,429	15,389	31,600	48.7%
MELS Plan	20,740	11,195	23,000	48.7%
Product sales in Japan	4,711	2,777	5,500	50.5%
Overseas	2,977	1,416	3,100	45.7%
Orthokeratology-related	15,001	7,656	14,500	52.8%
Other Contact lenses and Lens care products	63,456	33,249	68,000	48.9%
Healthcare and Life Care	9,304	4,276	8,600	49.7%

(Reference) MELS Plan sales for FY2024 are expected to be JPY 50.0 bn. MELS Plan sales for FY2024 2Q were JPY24.8 bn (49.8% progress)

Copyright: Menicon Co., Ltd. All rights reserved.

21


Sales Forecast for FY2024



22

Expand 1DAY-lens sales due to increase in supply and price revisions in Japan;

Decrease orthokeratology-related sales due to slow down in China, even after penetrating in Non-China regions.




Category	Forecast for 3Q and beyond	Factors Affecting Business Performance
1DAY-lens	Overall:OIncrease supplyJapan:OExpand sales channels and effect of price revision in JapanOverseas:△Adjust inventory in North America and China, etc.	
Orthokeratology-related	 Japan: O Expand penetration in Japan Overseas: △ Anticipate an increase in competition in China and intensification of competition due to alternative technology diffusion O Expand penetration in Non-China regions 	 Deteriorating competitive environment and changes in economic trends and national policy for Ortho-K in China Foreign exchange fluctuations
Other Contact lenses and Lens care products	 Japan: O Switch to high value-added products O Expand sales of hydrogen peroxide-type lens care products O Enjoy effect of price revision in Japan Overseas: O Enjoy effect of M&A of sales companies in Asia ⇒p.26 	

Operating Profit Forecast for FY2024

S Menicon

23

Expect increase in gross profit due to expand 1DAY-lens sales and price revisions in Japan. Appropriate control of SGA while planning investment expenses for future growth.




Vision Care

1DAY-lens Growth Strategies

Expand sales through unique SMART TOUCH package and region-specific sales strategies.

\enicon



Vision Care

Orthokeratology-related Growth Strategies


Expand market share by increasing orthokeratology lenses penetration and establishing a position as a specialist company offering multiple products.

\enicon

Strategy Main measures Expand sales in France by utilizing Dencott, a French fitting and sales company (employee **Promote sales with multiple products** training underway), and expand sales in other Europe in multiple countries countries. α Ortho-K: Highly customized **Ortho-K** Continue academic activities to raise awareness (Global) Menicon Z Night: High oxygen permeability/Soft wear to support prescription Expand sales by strengthening the sales Menicon Bloom Night: Myopia control management structure Japan Develop orthokeratology lenses to control myopia progression Lens Care Expand sales channels and strengthen sales promotion **Products** Promote sales through multiple channels (medical/EC) activities by taking advantage of group sales (Asia) Asia companies · Develop new lens care products in China (pending approval) BLOOM NIGH MEN CARL PLUS Manican Blacen Night 25

Expansion of Overseas Sales Channels: Strengthen Asian Sales Network

Formed an alliance with an online contact lenses retailer in China, where the disposable contact lenses market is expanding. Acquired a distributor in Southeast Asia in anticipation of medium- to long-term growth in demand.



Vision Care

Strengthening the Supply Chain: Production

Expand production system for 1DAY-lens, Ortho-K lenses and Lens care products in anticipation of mid- to long-term demand growth.

1DAY-lens



Singapore Plant Products: Magic Sales Area: Global Operation schedule: Line No.9-10 by FY2025 1H



Wuxi Plant

Orthokeratology-related

Products : α Ortho-K Sales area: China Reinforcement of production system to meet demand



Kakamigahara Plant Products : 1DAY Menicon PremiO Sales area: Global Operation schedule: Line No.11 in FY2024 2H Line No.12 in FY2026 2H



Gujo Plant

Products : Lens care products for Hard/Soft lenses Sales Area: Global Operation schedule: New Line in FY2025 1H



Malaysia Plant

Products: 1DAY-lens Sales Area: Global Operation schedule: Line No.1 in FY2025 2H Line No.2-5 by FY2026 2H

Copyright: Menicon Co., Ltd. All rights reserved.




27

Milestone 2027



28

Set quantitative targets at the midpoint (FY2027) of Vision 2030.





Reference

Copyright: Menicon Co., Ltd. All rights reserved.

29


Analysis of Changes in Operating Profit for FY2023 and Forecast for FY2024

Expand countries where products are sold and develop new products

R&D



Reviewed gross profit and SGA breakdown reflecting the current situation.




Copyright: Menicon Co., Ltd. All rights reserved.

(0.1)

(0.4)

Growth Strategy Targets & 1DAY-lens Regional Targets


Expect targets by implementing growth strategies.



1DAY-lens Sales Trends



Increase in 1DAY-lens sales due to increase production capacity.




Vision Care

1DAY-lens Sales Forecast (Breakdown of Sales)

Forecast growth in MELS Plan (increase in 1DAY-lens membership) and Overseas (sales expansion mainly in Europe and North America) due to increase production capacity.


Menicon

33



Vision Care Orthokeratology-related Sales Forecast (Breakdown of Sales)

Orthokeratology Lenses : Expect growth in Japan and other regions. Lens Care Products : Expect impact of economic stagnation in China and changes in the competitive environment.



34

Vision Care

Strengthening the Supply Chain: Logistics

Develop a logistics structure that has the capacity to handle an increase in the number of products and the volume of inventory, and to enable efficient operations in anticipation of medium- to long-term demand growth.

Established in March 2024

Menicon SC GmbH

Transfer of Menicon GmbH's distribution center management and operation functions

Target Area Mainly Europe



Global Logistics Center


Consolidation of logistics functions in Northern Japan (Miyagi pref.) and Komaki (Aichi pref.)

Target Area Overseas and throughout Japan (Kanto and north area)





Established in May 2024



Save manpower through automation and digitalization of operations, etc.


Aenicon

35


Close to major sales areas for efficient operations

S Menicon

Expect higher growth in EBITDA than operating profit due to the recognition of depreciation in line with capital expenditures.



Cost of Sales Ratio / SGA Ratio / Operating Profit Margin




Menicon

Expansion of Business Domain

Promote business expansion based on growth potential, uniqueness, and social contribution.

Menicon

38



Information Dissemination Tools of Menicon



- <u>Consolidated Financial Results (every quarter)</u>
- Financial data (every quarter)
- Databook

General business, strategic and non-financial

• Menicon report (once a year)



Copyright: Menicon Co., Ltd. All rights reserved.

Nenicon

Disclaimer on Forward-Looking Statements



Disclaimer

- This document was created by Menicon Co., Ltd. (hereinafter referred to as the "Company") for the purpose of understanding the current situation of the Company in order to serve as a reference for investors.
- The contents of this document have been prepared based on the generally recognized economic and social conditions as of November 13, 2024 and certain assumptions that the Company deems reasonable. The contents are subject to change without notice due to changes in the business environment
- · When making an investment, please be sure to make your own judgment.

Notes on forward-looking statements

- The document and information provided in this presentation include so-called "forward-looking statements". These are based on current expectations, forecasts and risks assumptions and contain uncertainties that could lead to results that are substantially different from these statements.
- These risks and uncertainties include general industry and market conditions, general domestic and international economic conditions such as interest rates and currency exchange fluctuations.
- Even if there is new information or future events, we are not obligated to update or revise the "outlook information" included in this announcement.

Contact information

